DPM&S produces approximately 50% of Dechra’s pharmaceuticals across our eight manufacturing sites, with the remaining 50% managed through external supply relationships. It’s objectives are to produce Dechra’s product range efficiently and to the highest quality standards maintaining a reliable supply chain and to contribute profit to the business through third party manufacturing.
A total of 901 employees worked in the DPM&S division as of the 2023 financial year end.
Our manufacturing sites at Skipton, Bladel and Zagreb also include Pharmaceutical Development, Quality Control (QC) and Stability Testing and Validation Laboratories.
The site at Skipton offers a comprehensive range of manufacturing and packing services, principally for CAP. It is a centre of excellence in solid forms for tablets and capsules, liquids, creams, ointment products and terminal sterilisation.
Bladel, the Netherlands
The site at Bladel manufactures water soluble powder and premix products for food producing animals in large-scale batches. It is also a centre for aseptic filling and for sterile injectables for both FAP and CAP.
Produces and develops egg based vaccines in addition to liquids in various scales and formats. It is currently being expanded to be a second source of solid dose tablets.
Fort Worth, Texas USA
This site manufactures solid dose, liquids, creams and ointments for the North American market.
Melbourne, Florida USA
It is a centre of excellence in manufacturing palatable and chewable tablets.
Produces a wide range of vaccines for multi species predominately for South America and selected export markets.
This site produces a broad portfolio of dosage types for the Australian and New Zealand markets including tablets and liquids.
Pomona, California USA
Med-Pharmex site acquired in August 2022. It has expertise in topical, oral and certain injectible products.